<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04640363</url>
  </required_header>
  <id_info>
    <org_study_id>S2020-387-03</org_study_id>
    <nct_id>NCT04640363</nct_id>
  </id_info>
  <brief_title>Combi-elastography Assessment of HCC Recurrence After Thermal Ablation Multi-center Study</brief_title>
  <official_title>Combi-elastography Assessment of HCC Recurrence After Thermal Ablation Multi-center Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese PLA General Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Combined F index, A index,ATT index and spleen stiffness to predict tumor recurrence in&#xD;
      different liver settings after thermal ablation of HCC.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Thermal ablation is one of the established method for HCC treatment. Postoperative recurrence&#xD;
      of HCC is one of the major factors leading to poor prognosis of HCC patients. Most studies&#xD;
      have shown that the risk factors of recurrence include tumor size, tumor number and&#xD;
      intrahepatic spread, etc.&#xD;
&#xD;
      Besides, the carcinogenic effects of inflammatory activity and fibrosis in liver background&#xD;
      caused by chronic hepatitis also be related to the recurrence. In the study,&#xD;
      combi-elastography imaging technology , not only the F index which is related to liver&#xD;
      fibrosis stage can be obtained, but also the A index which is related to inflammation&#xD;
      activity can be measured, this may provide a more valuable method for tumor recurrence of&#xD;
      early prediction.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2020</start_date>
  <completion_date type="Anticipated">May 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>F index</measure>
    <time_frame>baseline</time_frame>
    <description>F index is linked to the degree of liver fibrosis,and it can be available by ultrasound elastography checking.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>A index</measure>
    <time_frame>baseline</time_frame>
    <description>A index is linked to the degree of hepatitis,and it can be available by ultrasound elastography checking.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ATT index</measure>
    <time_frame>baseline</time_frame>
    <description>ATT index is linked to the degree of steatosis of liver,and it can be available by ultrasound elastography checking.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Spleen stiffness</measure>
    <time_frame>baseline</time_frame>
    <description>Spleen stiffness can be available by ultrasound elastography checking.</description>
  </primary_outcome>
  <enrollment type="Anticipated">300</enrollment>
  <condition>HCC</condition>
  <condition>Recurrence Tumor</condition>
  <eligibility>
    <study_pop>
      <textblock>
        patients who underwent thermal ablation of HCC will be observed and evaluate the predictive&#xD;
        power of combined elastography for tumor recurrence.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged 18 to 80 years of age, and gender not limited;Chronic hepatitis B patients;The&#xD;
             lesions of liver have the histopathological diagnosis of HCC and within MiLan&#xD;
             criteria;All lesions were performed thermal ablation surgery;Sign the informed&#xD;
             consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Lesions that unrealized complete inactivation evaluation by the enhanced&#xD;
             imaging;Merging other systems' serious illness that can't cooperate with elastic&#xD;
             imaging checking(such as heart failure, renal failure, such as mental illness);After&#xD;
             liver transplantation patients;Patients with pregnancy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ping Liang, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese PLA General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jie Yu, Doctor</last_name>
    <phone>010-66937981</phone>
    <email>yu-jie301@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ping Liang, Doctor</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>November 10, 2020</study_first_submitted>
  <study_first_submitted_qc>November 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 23, 2020</study_first_posted>
  <last_update_submitted>January 13, 2021</last_update_submitted>
  <last_update_submitted_qc>January 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese PLA General Hospital</investigator_affiliation>
    <investigator_full_name>Ping Liang</investigator_full_name>
    <investigator_title>Chief physician</investigator_title>
  </responsible_party>
  <keyword>Thermal ablation</keyword>
  <keyword>Elastography</keyword>
  <keyword>Ultrasound</keyword>
  <keyword>Recurrence</keyword>
  <keyword>Predictive Cancer Model</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

